Background: To examine the value of five-step platinum desensitization therapy in epithelial ovarian cancer Methods: A retrospective study was conducted on the high-grade serous adenocarcinoma of the ovary (HGSAO) patients who developed a platinum allergy during treatment an...
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer and has a poor outcome. It has been proposed that fallopian tube cancers may be precursors of HGSOC but evolutionary evidence for this hypothesis has been limited. Here, we perform whole-exome sequence and...
High-grade serous tubo-ovarian cancer (HGSTOC) is characterised by extensive inter- and intratumour heterogeneity, resulting in persistent therapeutic resistance and poor disease outcome. Molecular subtype classification based on bulk RNA sequencing facilitates a more accurate characterisation of this heterog...
The two most prevalent subtypes of epithelial ovarian carcinoma (EOC) are ovarian clear cell carcinoma (OCCC) and high-grade serous ovarian carcinoma (HGSC). Patients with OCCC have a poor prognosis than those with HGSC due to chemoresistance, implying the need for novel treatment target. In thi...
All patients with ovarian cancer had Stage III-IV high-grade serous adenocarcinoma (n = 33) and the majority of patients with a benign ovarian mass (n = 12) had a serous cystadenoma (75%). No ovarian pathology was found in the patients undergoing risk reduction surgery for a gen...
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma.MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma.doi:10.1186/s13048-015-0154-2To investigate magnetic resonance imaging (MRI) features for differentiating ovarian endomet...
2 Due to its pathological characteristics, ovarian cystadenocarcinoma tends to be typically larger in size and mucinous cystic adenocarcinoma is more massive than serous cystic adenocarcinoma. According to the literature,3 ovarian cystic adenocarcinoma has a minimum diameter of 4 cm. We hereby report a...
Treatment with PARP inhibitors (PARPi) is primarily effective against high-grade serous ovarian cancers (HGSOC) with BRCA1/2 mutations or other deficiencies in homologous recombination (HR) repair mechanisms. However, resistance to PARPi frequently devel
The cell-of-origin of high grade serous ovarian carcinoma (HGSOC) remains controversial, with fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) both considered candidates. Here, by using genetically engineered mouse models and organoids, we assessed the tumor-forming properties of...
Gill2, Kristie-Ann Dickson1,Ying Zhu3, Adele Clarkson2, Gregory B. Gard4, Jayne Maidens4, Susan Valmadre5, Roderick Clifton-Bligh1 & Deborah J. Marsh1 The tumour suppressor p53 is mutated in cancer, including over 96% of high-grade serous ovarian cancer (HG...